Apogee Therapeutics extends cash runway to 2029 as atopic dermatitis data deepens

Apogee Therapeutics (NASDAQ:APGE) ended the first quarter of 2026 with $1.3 billion in cash, cash equivalents, and marketable securities.

The strengthened balance sheet was bolstered by a $403 million upsized underwritten public offering completed during the period, which the company expects will fund operations through a planned Biologics License Application (BLA) filing for atopic dermatitis and extend its total cash runway into 2029.

The company’s lead program, zumilokibart, an extended half-life IL-13 antibody, reached a critical milestone with the release of 52-week maintenance data from the Phase 2 APEX trial.

The results demonstrated that patients with moderate-to-severe atopic dermatitis maintained high clinical response rates and even showed improved efficacy over time with dosing intervals as infrequent as every three or six months.

This sustained durability supports the company’s plan to initiate a global Phase 3 pivotal program in the second half of 2026.

Research and development execution remains the primary focus as Apogee prepares for late-stage clinical trials.

Beyond the primary atopic dermatitis indication, the company is evaluating the potential for zumilokibart in other TH2-mediated inflammatory diseases, leveraging the asset’s unique pharmacokinetic profile.

The significant capital infusion from the recent equity offering provides the necessary liquidity to advance multiple mid-to-late-stage programs simultaneously without the immediate need for additional financing.